Jakafi Oral Tablet
Jakafi (ruxolitinib) is a member of the multikinase inhibitors drug class and is commonly used for Myelofibrosis, Myeloproliferative Disorders and Polycythemia Vera.
- Availability:In Stock
- Minimum Order:20 Tablets
What is Jakafi?
Jakafi (ruxolitinib) works by blocking certain enzymes in the body that affect blood cell production.
Jakafi is used to treat myelofibrosis or polycythemia vera, which are bone marrow disorders that that affect your body's ability to produce blood cells.
Jakafi may also be used for purposes not listed in this medication guide.
You should not use Jakafi if you are allergic to ruxolitinib, or if you have severe kidney disease.
Before you take this medicine, tell your doctor if you have liver or kidney disease, if you are on dialysis, or if you are pregnant.
You should not breast-feed while you are using this medicine.
To be sure Jakafi is helping your condition and not causing harmful effects, your blood will need to be tested often. This will help your doctor determine the best dose for you to use. When you first start taking this medicine, your blood will need to be tested every 2 to 4 weeks. Do not miss any follow-up visits to your doctor.
Grapefruit and grapefruit juice may interact with Jakafi and can affect the amount of the medication in your blood. Discuss the use of grapefruit products with your doctor.
Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.
Before taking this medicine
To make sure Jakafi is safe for you, tell your doctor if you have ever had:
any type of chronic infection;
kidney disease (or if you are on dialysis);
liver disease (especially hepatitis B);
skin cancer; or
high cholesterol or triglycerides (a type of fat in the blood).
Tell your doctor if you have ever had tuberculosis, or anyone in your household has tuberculosis. Also tell your doctor if you have recently traveled. Tuberculosis and some fungal infections are more common in certain parts of the world, and you may have been exposed during travel.
Using Jakafi may increase your risk of developing skin cancer. Talk to your doctor about this risk and what skin symptoms to watch for.
It is not known whether ruxolitinib will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
You should not breast-feed while you are using ruxolitinib, and for at least 2 weeks after your last dose.
Jakafi is not approved for use by anyone younger than 18 years old.
Jakafi side effects
Get emergency medical help if you have signs of an allergic reaction to Jakafi: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may be similar to the symptoms of myelofibrosis. Call your doctor at once if you have:
blisters or painful skin rash;
changes in the size, shape, or color of a mole or skin lesion;
problems with speech, thought, vision, or muscle movement (these symptoms may start gradually and get worse quickly);
nausea, vomiting, weakness, general ill feeling;
pain or burning when you urinate;
low blood cell counts - fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath; or
signs of tuberculosis: fever, cough, night sweats, loss of appetite, weight loss, and feeling very tired.
Common Jakafi side effects may include:
low platelets (easy bruising);
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
Your email address will not be published.